Purpose: Epidermal growth factor receptor (EGFR)-targeted therapy is in clinical use to treat squamous cell carcinoma of the head and neck and other cancers of lining epithelium. RAS mutations in these tumors are a negative prognostic factor for response, and skin inflammation is an adverse reaction to therapy. We investigated transcriptional and biochemical changes that could account for the confounding effects of RAS activation and inflammation in a squamous tissue.
Introduction
The epidermal growth factor receptor (EGFR) is a transmembrane cell surface tyrosine kinase in the ErbB family. At least 5 ligands are known to activate EGFR kinase activity directly, and kinase function can be activated indirectly through interactions with neighboring receptors. Upon ligand binding, EGFR may either homoor heterodimerize resulting in autophosphorylation on several specific tyrosine residues. A number of intracellular substrates are phosphorylated by activated EGFR kinase resulting in stimulation of downstream pathways, including the RAS/MAPK pathway and PI3K/AKT pathway among others (1) . EGFR activity is increased in a number of human cancers by amplification, mutation, or ligand excess and, therefore, EGFR has become a target for anticancer therapy. Erlotinib (Tarceva, OSI-774), currently approved to treat non-small-cell lung cancer (NSCLC) and advanced pancreatic cancer (2) , selectively and reversibly, inhibits the EGFR tyrosine kinase by binding the intracellular ATP binding domain (3) . Cetuximab, an anti-EGFR monoclonal antibody that blocks ligandinduced EGFR activation, is currently approved for metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (HNSCC). RAS mutations occur in 15% to 30% of NSCLC (4) , in 30% to 50% of mCRC (5) , 60% to 80% of pancreatic cancers (6, 7) , and 5% to 8% of HNSCC. In NSCLC, HNSCC and mCRC RAS mutations are negative prognostic factors (8) . Patients with tumors harboring RAS mutations that are treated with EGFR-targeted therapy are less or nonresponsive or may have decreased survival, as compared with chemotherapy alone (9, 10) . In addition, patients on anti-EGFR therapy often suffer from a severe acneiform, papulopustular folliculitis that involves the face, scalp, chest, back, and arms, characterized by neutrophilic infiltration in the infundibular portion of the hair follicle, alopecia and xerosis cutis unresponsive to standard therapy (11, 12) . Although the extent of the skin rash often correlates with positive clinical response in responsive patients (13) , evaluating the RAS gene status before dispensing an EGFR inhibitory drug will reduce rash-associated morbidity.
A promising model to evaluate the interaction of the RAS and EGFR pathways experimentally is the EGFR null mouse that recapitulates the dose-limiting rash of anti-EGFR therapy as a fulminant papulopustular neutrophilic folliculitis that consumes the hair follicles leading to alopecia (14) . Oncogenic ras-transformed keratinocytes from EGFR null mice produce squamous tumors as orthografts, and these tumors have a high proliferation rate in the absence of EGFR, even though the tumors are very small (15) . We hypothesized that specific changes in gene expression induced by oncogenic ras in this squamous tumor model could illuminate pathways contributing to the poor clinical response of tumors harboring RAS mutations in patients on anti-EGFR therapy. In this study, we have compared the cell autonomous phenotype of EGFR genetic deficiency with acute pharmacologic ablation of the pathway by anti-EGFR therapeutics in skin keratinocytes, with and without an activated mutant Ras oncogene. We find substantial transcriptional differences among these groups and define a signature for each. Furthermore, pathway analysis and biochemical experiments revealed an unexpected activation of p38 signaling that is unique to the oncogenic ras-EGFR-ablated phenotype. Suppression of p38 signaling inhibits growth of EGFR-ablated keratinocytes oncogenically transformed by activated Ras.
Materials and Methods

Materials
Erlotinib (Tarceva) was supplied by OSI Pharmaceuticals Inc., AG1478 was purchased from Sigma-Aldrich, PD153035 and SB203580 were purchased from Calbiochem Inc. All drugs were dissolved in dimethyl sulfoxide.
Mouse model
Mouse studies were done under a protocol approved by the National Cancer Institute (NCI) and NIH Animal Care and Use Committee. Homozygous and heterozygous EGFR null mice and wild-type siblings on CD-1 background have been described previously (14) .
Cell culture
Primary mouse keratinocytes were isolated from newborn EGFR-deficient and wild-type mice. Keratinocytes were prepared as described previously (16) and cultured in calcium-and magnesium-free MEM (Invitrogen Life Technologies) supplemented with 8% Chelex-treated (Bio-Rad Laboratories) FBS (Gemini Bioproducts) and 0.2 mmol/L Ca 2þ . After 24 hours, cultures were switched to the same medium with 0.05 mmol/L Ca 2þ to select for basal cells and cultured for 2 additional days. Transduction of v-ras Ha into keratinocytes (termed ras-keratinocytes) employed a replication defective retrovirus as described previously (17) . Viral infections were done using diluted supernatant from y-2 producer cells. Cells were cultured for 4 days following v-ras Ha transduction and then treated with 1 mmol/L of the various EGFR tyrosine kinase inhibitors for 2 hours or 14 hours. Nontransduced cells were treated on day 4 after plating and at the same concentration and time points as the v-ras Ha -transduced keratinocytes. The same protocol was used to infect cells with retrovirus encoding Kras v12 generated by transfecting a Platinum A retroviral packaging cell line (Cell Biolabs, Inc) with pBabe K-Ras V12 (Addgene) and harvesting medium 48 hours later for infection of keratinocytes. Human keratinocyte HaCaT cells (18) were cultured in Dulbecco's modied Eagle's medium (DMEM) with 10% FBS. Human RAS-transformed keratinocytes HaCaT-II-4 were provided by Dr. Jonathan Garlick (Tufts University) and cultured in low-glucose DMEM with 5% FBS, 10 mmol/L HEPES, and Pen/strep (Life Technologies/Invitrogen).
Microarray design and biometric analysis
Ten microgram total RNA from tissue culture samples or mouse universal reference total RNA (Stratagene) were reverse transcribed and the cDNA coupled to Cy3 or Cy5 dyes (Amersham Biosciences), respectively, using the indirect labeling procedure as previously described (19) . The labeled Cy3 and Cy5 cDNA was purified using QIAGEN PCR Cleanup kit (QIAGEN Inc.). For each microarray, Cy3-labeled cDNA was cohybridized with Cy5-labeled cDNA and compared on each slide. Reverse-fluor experiments were included for each group. Each group contained 5 biological repeats. The labeled cDNAs were mixed with
Translational Relevance
A major advance in targeted cancer therapy was accomplished by the introduction of epidermal growth factor receptor (EGFR) antagonists for the treatment of lung, head and neck, and colon cancer. However, efficacy is limited due to the frequent presence of RAS gene mutations in these tumor types, an adverse skin eruption, and the development of resistance. This article utilizes a well-described model of oncogenic Ras-transformed keratinocytes, gene expression profiling, and a highly restrictive analytic approach to identify unique expression signatures that define the influence of activated Ras on acute and chronic EGFR ablation therapy in a squamous tumor type. Combined with biochemical studies, the analysis has revealed several previously unrecognized functional alterations unique to the Ras-EGFR ablation interaction that could be targets for combination therapy to overcome therapeutic failure.
Mouse Cot-1 DNA, yeast tRNA, and polydA and boiled for 2 minutes prior to hybridization on microarray slides at 42 C for 14 t 16 hours. Poly-L-lysine-coated glass slides, containing approximately 37K mouse oligoarray features, were obtained from the NCI Microarray Core Facility. After hybridization, the slides were washed in SSC, dried, and scanned using GenePix 4000 microarray scanner (Axon Instruments) with Genepix 4.0 software. Spots with a size of less than 10 mm or an intensity of less than 100 in both the red and green channels were eliminated, followed by removal of features that were uninformative in more than 50% of available arrays. Each array was normalized using a Lowess with print-tip group to provide intensity-dependent normalization.
Statistical analyses were done using the BRB-ArrayTools package (version 3.4.0) developed by Dr. Richard Simon and BRB-ArrayTools Development Team for microarray analysis. Class comparison analysis was done using the expression data. The 2-sample t statistic with random variance model (20) was used to measure the difference in gene expression between 2 classes. Genes were considered as being differentially expressed at a significance of P 0.01.
The data discussed in this article have been deposited in NCBI's Gene Expression Omnibus (21) and are accessible through GEO Series accession number GSE29415.
Ontology
GoMiner and EASE analyses were done on the lists of differentially expressed genes (22, 23) . Enrichment of categories was determined using GoMiner, and P value thresholds were determined from EASE scores.
Ingenuity pathway analysis
Data sets containing the NCI probe set identifiers and fold changes were uploaded into Ingenuity Pathway Analysis software (IPA). The IPA program searches the Ingenuity Pathway Knowledge Base (IPKB) for interactions between the uploaded genes and all other genes in the IPKB and generates a series of networks. Fisher exact t test was used to assign statistical significance, and biological functions were also assigned to each network.
Quantitative real-time PCR
RNA was isolated using TRIzol (Invitrogen). cDNA synthesis and real-time PCR analysis was previously described (24) .
Immunoblotting
Cultures were washed twice with PBS, and total cell lysates prepared with 1% triton containing lysis buffer (Cell Signaling) supplemented with 1 mmol/L phenylmethylsulfonylfluoride, Halt Phosphatase Inhibitor (Pierce) and Mini-complete tablets (Roche). Proteins were quantified with the Bradford method (Bio-Rad) and separated by a 4% to 20% SDS-PAGE gel. Phospho-EGFR (Invitrogen), EGFR, p38a, p38d (Santa Cruz), p38 and phospho-p38 (Cell Signaling) were used at 1:1,000 overnight at 4 C, b-actin (Chemicon) was used 1:10,000 for 1 hour room temperature. Enhanced chemiluminescence SuperSignal (Pierce) system was used for detection.
Immunohistochemistry
Serial sections of 5-mm paraffin embedded tumors were treated with 3% hydrogen peroxide to inhibit peroxidase activity, blocked in Dako blocking solution (Dako) and incubated overnight with phospho-p38 (Cell Signaling) and phospho-EGFR antibodies. The next day sections were treated with goat anti-rabbit-HRP (horseradish peroxidase) and sheep anti-mouse HRP (GE Healthcare), respectively, at 1:500 dilution. Immunoreactivity was detected using the DAB kit (Vector Laboratory).
H-Thymidine incorporation assay
Keratinocytes, EGFR wild type and EGFR null, were plated in 24-well plates and transduced with v-ras Ha or K-ras V12 as described. Five days later, cells were treated with the appropriate EGFR TKI for 14 hours. For cotreatments, cells were pretreated with p38 inhibitor for 4 hours at 10 mmol/L. Hthymidine (1 mCi per well) was added for 3 hours. Cells were fixed using methanol and acetic acid (3:1 ratio), solubilized with NaOH (5 normal), and incorporated counts were read using a scintillation counter.
0 , and All Stars negative control siRNA were obtained from Qiagen and transfected using HiPerfect (10 nmol/L; Qiagen) according to the manufacturers protocol. All siRNA transfections were done 3 days after v-ras Ha transduction. Thirty-two hours posttransfection, EGFR wild-type cells were treated with AG1478, erlotinib, or PD153035 for 14 hours, rinsed with PBS and collected for total protein isolation.
Results
Gene expression profiles of EGFR-ablated rastransformed keratinocytes
Our goal was to identify a gene expression signature common to genetic and pharmacologic ablation of EGFR in the context of oncogenic Ras transformation. To achieve this end, we transformed wild-type mouse keratinocytes or EGFR null keratinocytes with a v-ras Ha retroviral vector and isolated RNA 2 hours after treatment with EGFR inhibitors. To identify differentially expressed genes, class comparisons were done and genes selected with a P 0.01. When compared with EGFR wild-type keratinocytes transduced with v-ras Ha , this analysis yielded differentially expressed gene lists for AG1478, erlotinib, PD153035, and EGFR null of 852, 1054, 928, and 758, respectively (Fig. 1A) . To determine gene expression off-target effects of the EGFR pharmacologic inhibitors, EGFR null v-ras Ha keratinocytes were treated with AG1478, erlotinib, or PD153035. Class comparisons between treated and untreated EGFR null v-ras keratinocytes gave off-target gene lists of 891, 380, and 2,486 of differentially expressed genes for AG1478, erlotinib, and PD153035, respectively.
To understand the activated Ras effect on keratinocytes, it was also necessary to identify a signature common to genetic and pharmacologic ablation of EGFR without HA -transformed keratinocytes were treated with each EGFR inhibitor for 2 hours, RNA was isolated, and expression changes relative to untreated transformed keratinocytes were documented using the 37K mouse oligo array platform. A master EGFR gene list was similarly generated from the profile of v-ras Ha -transformed EGFR null keratinocytes that overlapped a comprehensive map of EGFR signaling (ref. 27; light blue), and these lists were intersected to identify common genes that were EGFR relevant. These 3 overlapped gene lists were then intersected and shown in the Venn diagram, discordant genes were removed, and a resultant list of 34 common genes was identified. By treating oncogenic Ras-transformed, EGFR null keratinocytes with the 3 EGFR inhibitors, off-target gene expression changes were identified, and 9 genes in the 34 concordant gene list were removed as off target genes. This resulted in 25 genes that comprised the Ras-EGFR ablation signature. B, a Venn diagram illustrates the similar analysis used to determine the common and concordant genes between the 4 methods of EGFR ablation in the absence of oncogenic Ras. Each gene expression profile is from 5 biological repeats. Ras-mediated transformation. To achieve this, 4 days after plating, we isolated RNA 2 hours after treatment of wildtype keratinocytes with EGFR inhibitors. RNA was also collected from EGFR null keratinocytes on day 4 after plating. As in the Ras-transformed comparisons, all differentially expressed gene class comparisons were done with a P 0.01. When compared with untreated EGFR wild-type keratinocytes, treated keratinocytes yielded differentially expressed gene lists for AG1478, erlotinib, PD153035, and EGFR null of 450, 165, 229, and 3,137, respectively (Fig.  1B) . These array comparisons express the difference between an acute blockade of EGFR by inhibitors and a chronic shutdown of the EGFR signaling by genetic ablation in keratinocytes. Whereas the EGFR inhibitor-treated groups have relatively small numbers of gene expression changes, the EGFR null array comparison has more than 10-fold higher number of changes, expressing the myriad of consequences of chronic inhibition of EGFR on wild-type keratinocytes. Furthermore, the introduction of oncogenic ras into the genome adds significantly more complexity to the acute response to inhibitors but reduces the number of differentially expressed genes in keratinocytes chronically depleted of EGFR by gene ablation. This suggests that there are a significant number of common changes in gene expression produced by Ras transformation and EGFR activation.
To verify our microarray data, we conducted quantitative real-time PCR for 25 differentially expressed genes. Supplementary Table S1 shows the fold change for both the realtime PCR and the microarray. All genes screened were concordant in direction of expression and, for the most part, similar in magnitude between the real-time data and microarray data.
Identification of signatures for EGFR ablation
To identify commonly expressed genes between the different methods for EGFR ablation, an EGFR master list was created. The master list was created by combining the differentially expressed genes of the microarray comparison between EGFR wild-type v-ras Ha keratinocytes and EGFR null v-ras Ha keratinocytes, and genes that have been cataloged from a comprehensive map of EGFR signaling (25) . This EGFR master list of 789 genes serves as the basis for further analysis and comparison with the samples treated with chemical EGFR inhibitors. A 4-step analysis (Fig. 1A) was carried out; comparison of gene lists from AG1478-, erlotinib-, or PD153035-treated v-ras Ha keratinocytes with EGFR master list, overlapping genes between the EGFR inhibitors and the EGFR master list to find commonalities, and removal of discordant genes. At this point, the analysis had yielded 34 genes. To ensure no genes involved in off-target effects were included, we intersected the 34 genes with the 3 off-target gene lists; this filtered out 9 genes to achieve a 25-gene list. This gene list is a signature for EGFR ablation in keratinocytes when v-ras Ha is activated (Table 1) .
To create a signature for EGFR ablation in the absence of oncogenic ras, we carried out similar comparisons as above.
The array comparison between EGFR wild-type keratinocytes and EGFR null keratinocytes yielded 3,137 differentially regulated genes, and there was significant overlap with the comprehensive map (25) . The 3 EGFR inhibitor array gene lists were intersected with the EGFR null gene list, resulting in an overlap of 19 genes (Fig. 1B) . All 19 genes were concordantly expressed between the different methods of EGFR ablation (Table 2) . Surprisingly, there was no overlap among the gene lists with and without oncogenic Ras, although both showed downregulation of a member of the dual specificity kinase family (Dusp 1 and Dusp 9). This suggested that oncogenic Ras exerts a strong influence on the consequences of EGFR inhibition in keratinocytes.
Gene ontology and pathway analysis
Gene ontology categories from the total gene lists of Fig.  1A and B that are significantly enriched in the 4 methods of EGFR ablation in the presence of oncogenic Ras are shown in Supplementary Table S2A-D. The cut-off for all ontology analysis was an EASE score of 0.05 or lesser. The color is based on the average fold change of the genes matching to specific ontologies, thereby giving information as to the over-all expression direction of the ontology. Each inhibitor had a unique ontology profile, although some general overlapping areas could be discerned. Among the gene categories for EGFR ablation are ATPase activity, regulation of transcription, MAPKKK cascade, cell proliferation, ion transport, and enzyme inhibitor activity. To better understand the effects of pharmacologic inhibition, we catalogued the genes that are common and concordant between the 3 inhibitors. Supplementary Table S2E shows the ontologies enriched from the 109 genes that overlapped the 3 methods of acute pharmacologic blockade. A predominant theme arising from this analysis is the frequency of enrichment in ontologies for ion, cation, and chemical homeostasis. To further understand the core differences between acute (erlotinib) and chronic (EGFR null) inhibition in the presence of oncogenic Ras, we removed overlapping or related ontologies and showed the remaining unique ontologies in Supplementary Table S2F . Chronic depletion by gene ablation depresses genes encoding proteins involved in transcription, cell growth, and cell-cycle regulation. In contrast, acute exposure to erlotinib emphasizes an upregulation of genes encoding metabolic enzymes and stress responses, a change common to all of the inhibitors.
Supplementary Tables S3A-D are enriched ontologies from the 4 methods of EGFR ablation in the absence of oncogenic Ras transformation. There is almost no overlap in enriched ontologies between the different methods of EGFR ablation. Only a few gene ontologies, particularly related to cell adhesion and motility, are commonly enriched. The 3 chemical inhibitors do share similar immune-related ontologies, which are chemokine activity, inflammatory response, and immune response. These changes could be associated with an inflammatory response mediated through EGFR inhibition in skin keratinocytes. In the absence of oncogenic Ras transformation, the diversity and extent of gene ontology changes is much greater when comparing EGFR wild-type to null keratinocytes, than when comparing EGFR wild-type keratinocytes to keratinocytes acutely ablated for EGFR. By examining ontologies based only on the 25 genes v-ras Ha -EGFR ablation signature (Supplementary Table S4 ), 5 enriched ontologies encompassing the same genes became apparent. These ontologies define common functions as membrane transporters.
Using Ingenuity Pathway Analysis (IPA) and its Ingenuity Pathway Knowledge Base (IPKB), we investigated interactions among the v-ras Ha -EGFR ablation signature gene list and found that 14 of the 25 genes mapped to one network shown in Fig. 2A . With a score of 33, this network relates to cancer, cellular growth and proliferation, cellular development, and tumor morphology. Central to this network is the p38 MAPK (mitogen-activated protein kinase). The same analysis was done on the EGFR ablation signature gene list in the absence of v-ras Ha transformation and illustrated that 11 of the 19 genes mapped to one network. The network (Fig. 2B) was the most significant and has a score of 26. Top functions of this network related to immune cell trafficking, cellular growth and proliferation, and cellular assembly and organization. Central to this network are Erk1/2 and interleukin (IL)-1b.
p38MAPK is activated by EGFR ablation in the presence of ras activation
The MAPK p38 is a potent regulator of proliferation, inflammation, cell motility, and differentiation. The p38 MAPK family includes p38a, b, d, and g, with 3 isoforms expressed in keratinocytes, a, b, and d. The isoforms affect different cellular processes. On the basis of IPA mapping of p38 interaction with the v-ras Ha -EGFR ablation signature, we tested the effects of EGFR inhibition on modification of the p38 isoforms. Pharmacologic or genetic ablation of EGFR in combination with v-ras Ha increases phosphorylation of p38 in cultured primary keratinocytes, without changes in overall levels of p38a, p38b, or p38d (Fig. 3A) . Proliferation as determined by 3 Hthymidine incorporation (Fig. 3B) did not change in Rastransformed keratinocytes with either genetic or pharmacologic ablation of EGFR. In contrast, genetic and pharmacologic ablation of EGFR inhibited proliferation in wild-type keratinocytes. To confirm that the changes in p38 activation also occurs in vivo, squamous tumors arising from orthotopic grafts of EGFR wild-type and null v-ras Ha -transformed keratinocytes were immunostained for phospho-p38 (Fig. 3C and D) . In the absence of EGFR, phospho-p38 is abundantly detected in basal and suprabasal compartments of v-ras Ha oncogene-induced tumors, whereas detection is limited to a smaller number of cells restricted to the basal cell compartment in v-ras Ha -induced tumors expressing EGFR. Consistent with the in vitro results, previous analysis of these tumors indicated that proliferation rate in tumor epithelium was independent of EGFR status (15) .
p38a is the activated isoform of p38 in EGFR-ablated cells
To determine the specific p38 isoform activated by oncogenic Ras, when EGFR signaling is abrogated, isoformspecific p38 siRNA was used to selectively silence transcription. In either EGFR null cells or EGFR wild-type cells transformed with v-ras Ha , the level of phospho-p38 was reduced by siRNA targeting p38a but not p38b or p38d (Fig. 4A) . Because p38b is undetectable by immunoblot, we confirmed the effectiveness and specificity of the siRNA by real-time PCR (Supplementary Fig. S1 ). We inhibited p38 pharmacologically in v-ras Ha -transformed keratinocytes to determine whether combination treatment with EGFR ablation would lead to growth inhibition. Blockade of EGFR or p38 alone did not reduce proliferation, but combining inhibition of EGFR and p38 reduced proliferation by 40% to 45% (Fig. 4B) . We also asked whether p38 isoform knockdown would alter a sampling of genes differentially expressed as the EGFR ablation signature in wild-type keratinocytes transformed by oncogenic Ras and treated with erlotinib. In this signature, neuroregulin 1 (Nrg1) is downregulated whereas Id2 and Slc30a1 are upregulated.
Knockdown of the individual p38 isoforms does not reverse this trend (Fig. 4C) . Similar results were seen with Dusp1 and Timp3, also part of the EGFR ablation signature (data not shown). 
is detected in human keratinocytes
To confirm that changes in the v-ras Ha -EGFR signature detected in mouse keratinocytes were relevant to human keratinocytes, HaCaT and oncogenic RAS-transformed HaCaT II-4 cells (26) were employed. As seen in mouse keratinocytes, phospho-p38 was increased in the HaCaT II-4 cells when EGFR was pharmacologically abrogated (Fig. 5A ), but this response was not seen in the parental HaCaT cells. This result is consistent with previous finding in primary human keratinocytes in which pharmacologic inhibition of EGFR did not affect the level of phospho-p38 (27) . Furthermore, signature v-ras Ha -EGFR gene expression changes such as upregulation of Slc30a1, Id2, and Timp3 were increased upon EGFR inhibitor treatment, specifically in the HaCaT II-4 cells (Fig. 5B) . K-RAS mutations are more commonly found in NSCLC than H-RAS mutations. To ensure that our v-ras Ha -EGFR ablation signature was not limited to v-ras Ha activation, but applied to K-ras V12 activation as well, we infected mouse keratinocytes with retroviruses expressing either K-ras V12 or v-ras Ha ( Supplementary Fig. S2 ) and treated them with EGFR inhibitors. Gene expression changes seen in the v-ras Ha -EGFR signature were also observed in the K-ras V12 expressing cells when inhibited for EGFR. Such gene expression changes seen were upregulation of Timp3 and Id2 and downregulation of Dusp1 (Fig. 5C) . 
Discussion
It is now well established that activating mutations in one of the RAS alleles is a negative prognostic factor for response to EGFR ablation therapy in multiple epithelial cancer types (9, 28, 29) . We used an established mouse model for oncogenic v-ras Ha -induced squamous cancer to profile gene expression changes that might illuminate genes or pathways that define Ras signaling in the absence of EGFR and, therefore, be potentially relevant to therapy. To narrow our analysis, we required that both acute pharmacologic ablation and chronic genetic ablation of EGFR be included and the genes limited to those recognized under the comprehensive map of the EGFR pathway (25) . With these restrictions, we were able to identify a 25-gene signature for further pathway analysis. By carrying out the same analysis on cells treated identically, but without v-ras Ha transduction, a distinct 19-gene signature was generated. The absence of overlap in the 2 gene lists reveals the importance of Ras signaling in cells lacking EGFR signaling. The study also revealed differences in gene expression and ontologies among chronic genetic EGFR ablation that may model extended human drug exposure and acute pharmacologic ablation consistent with initiation of treatment. Several unexpected results became evident from this experimental design. In the absence of EGFR signaling, Ras activation has substantial influence on the expression of genes in ontologies for ion channels and membrane transporters. Furthermore, pathway analysis and biochemical studies indicate 
that activation of p38a is a response to both acute and chronic abrogation of EGFR signaling under conditions of Ras activation. This was also observed in oncogenic RAStransduced human keratinocytes and in tumor grafts of v-ras Ha -transformed mouse keratinocytes. Changes in membrane ion transporters and p38a signaling could influence the therapeutic response to EGFR ablation therapy in tumors driven by oncogenic RAS.
Because these studies were done on normal and v-ras Ha -transformed keratinocytes, they may be most relevant to NSCLC and HNSCC patients with similar lining epithelia, but the biology is analogous in CRC. RAS mutations range from 5% to 40% in these tumor sites depending on ethnicity and smoking history among other factors (28) (29) (30) . Whereas H-RAS mutations are more common in HNSCC, K-RAS mutations are more common in NSCLC. A sampling of our signature changes indicates that similar results are obtained with either mutant RAS allele. These inherent differences of cancers with and without RAS mutations and the correlation to responsiveness with EGFR-targeted therapy is mirrored in the distinct gene expression profiles documented in our model system using mouse keratinocytes ablated for EGFR signaling in the presence or absence of mutant ras. We noted distinct ontologies when oncogenic Ras was introduced into cells with chronically ablated EGFR (null keratinocytes) or acutely inhibited EGFR signaling (erlotinib). Genes involved in cell-cycle and transcriptional regulation are reduced with chronic depletion of EGFR, whereas acute inhibition is characterized by upregulation of transporters and stress-related genes. Among the latter are increased expression of Ryanodine receptor and Atp2b3 (Pmca3) that are critical for Ca 2þ transport and Ca 2þ intracellular homeostasis. Overexpression of Atp2b3 increases the export of intracellular calcium (31); thus lowering intracellular Ca 2þ levels, a change that has been associated with chemoresistance (32, 33) . It is well documented that altered calcium signaling in cancer cells contributes to tumor proliferation and progression, and molecules in the family of Atp2b3 participate in these alterations (34) . Indeed, previous gene expression profiling of human lung cancer cell lines, validated on resected adenocarcinomas and related to clinical response, revealed a 180-gene signature predictive of response to erlotinib that included multiple calcium signaling proteins, including CaM kinase and Atp2c1, a member of the Atp2b3 family (35) . These same genes are represented in a 26-gene signature predicting response to cetuximab in human colon cancer (36) . However, from the available data the concordance with our findings cannot be confirmed.
Pathway analysis of gene expression changes revealed that inhibition of EGFR in cells with wild-type Ras proteins intercepted pathways centering on nodes for Erk and IL-1b signaling. These pathways would be relevant for normal tissues exposed to EGFR inhibitors for cancer therapy and could be associated with the acneiform skin rash so prevalent in these patients. Activation of the MAPK pathway is a feature of the skin rash in patients receiving erlotinib for metastatic breast cancer (37) . Similarly, anti-IL-1 therapy reduces the skin eruption in a mouse model for the human rash (38) . We identified a unique activation of p38a as a consistent response in Ras-transformed mouse and human keratinocytes after either acute or chronic EGFR ablation. This is associated with a consistent decrease in expression of Dusp1, the primary phosphatase responsible for deactivating p38a. Previous studies have indicated distinct functions for the 4 members of the p38 family. p38a contributes to multiple cellular responses and can mediate inflammation, proliferation, and cellular differentiation depending on cell type and context (39, 40) . Activation of p38a is also associated with cancer cell proliferation (41) (42) (43) and invasion (44) . p38a antagonists are under study as therapy for both inflammatory and neoplastic diseases alone or in combination with other targets (40, 42, 45, 46) . In human keratinocytes, p38a activation is required for migration on collagen 1 and release of MMP13 in RAS-transformed keratinocytes (47) . Thus, activation of p38a might worsen the response to EGFR ablation therapy in Ras-driven tumors, and this has been observed in some cases. Our in vitro studies confirm that inhibiting p38 in oncogenic Ras/ EGFR-ablated keratinocytes reduces cell proliferation substantially, suggesting that a combination of EGFR and p38a inhibition could be clinically useful under similar circumstances.
In this study, we have been able to define gene expression changes in keratinocytes before and after anti-EGFR therapy in a setting of potential therapeutic success or failure dependent on the presence of a ras oncogene. As far as we can tell, only 2 previous studies have addressed tumor gene expression before and after treatment, and these were conducted with human metastatic breast cancers or breast cancer cell lines (48, 49) . The large array platform we employed and the stringent requirements we used to restrict the analysis to genes only associated with EGFR signaling and consistent among multiple EGFR antagonists were designed to illuminate the most relevant gene changes attributable to therapy in a squamous tissue. We also incorporated both acute and chronic EGFR inhibition in our requirements. Despite the restrictions we imposed to get the most specific and relevant set of markers possible, expression changes in Serpine1, Tenascin C, Cdc6, Atp2b3, Foxd3 in our signatures were concordant with the same or closely related genes identified as the top changes in the breast cancer analysis. Of particular interest was the common finding of 3 minichromosome maintenance protein genes (MCM3, 6, and 7) commonly downregulated in our EGFR null gene list (Supplementary Table S3D ) and breast cancer cells sensitive to lapatinib (53). These proteins are critical for DNA replication and cell-cycle progression, ontologies commonly found suppressed by chronic EGFR ablation. Our approach offered an opportunity for the first time to explore functional pathways associated with the potential for treatment success or failure. We have identified alterations in calcium balance and p38 signaling as changes unique to oncogenic Ras transformation in the setting of EGFR inhibition and thus possible targets to overcome treatment resistance. With therapeutics now available to target each of these alterations, future studies can address the potential efficacy of combinations to achieve full tumor inhibition.
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